Related Experiment Video

Updated: Mar 20, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

11.2K

A Case of Organizing Pneumonia (OP) Associated with Pembrolizumab

Paraskevi Fragkou1, Maria Souli1, Maria Theochari2

  • 1Fourth Department of Internal Medicine, Infectious Diseases Unit, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.

Drug Target Insights
|June 4, 2016
PubMed

Insights

Pembrolizumab, an anti-PD-1 therapy for metastatic melanoma, may cause organizing pneumonia. This is a rare side effect requiring clinical awareness for early diagnosis and management.

Area of Science:

  • Oncology
  • Pulmonology
  • Immunology

Background:

  • Metastatic melanoma treatment has evolved with immune checkpoint inhibitors.
  • Monoclonal antibodies targeting CTLA-4 and PD-1/PD-L1 have improved outcomes.
  • These immunotherapies introduce unique side effect profiles.

Observation:

  • A case of organizing pneumonia was identified.
  • Diagnosis was based on imaging and bronchoalveolar lavage cytology.
  • The patient was undergoing treatment with pembrolizumab for metastatic melanoma.

Findings:

  • Organizing pneumonia is a potential adverse event associated with anti-PD-1 therapy.
  • This specific case highlights a possible link between pembrolizumab and this pulmonary complication.
  • Cytological and imaging findings supported the diagnosis.

Implications:

  • Clinicians must be aware of potential pulmonary side effects of pembrolizumab.
  • Early recognition and management of organizing pneumonia are crucial in patients receiving immunotherapy.
  • This case contributes to understanding the safety profile of novel melanoma treatments.
Keywords:
OPmelanomaorganizing pneumoniapembrolizumabside effect

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis07:51

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

1.3K
Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia08:05

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia

Published on: December 19, 2020

14.9K

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
1.2K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.9K
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
1.1K
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
3.9K
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease...
2
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.0K